NMTC NEUROONE MEDICAL TECHNOLOGIES Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: NMTC

Price (delayed)

$1.34

Market cap

$12.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$10.23M

?
Relative Growth: Rel. Growth: 37
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 25
Relative Profitability: Rel. Profitability: 14
Highlights
The company's debt has shrunk by 58% YoY and by 21% QoQ
NMTC's revenue is up by 3% since the previous quarter
NEUROONE MEDICAL TECHNOLOGIES's gross profit has decreased by 22% YoY but it has increased by 5% QoQ
The gross margin is down by 21% YoY but it is up by 2.2% QoQ
The quick ratio has shrunk by 73% YoY and by 45% QoQ
NEUROONE MEDICAL TECHNOLOGIES's equity has plunged by 54% YoY and by 26% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.n1mtc.com
Peers: OBIO OM

Key stats

What are the main financial stats of NMTC

NMTC stock price

How has the NEUROONE MEDICAL TECHNOLOGIES stock price performed over time
Intraday
-2.9%
1 week
-4.96%
1 month
-33.99%
1 year
-76.33%
YTD
-70.55%
QTD
-55.92%

Financial performance

How have NEUROONE MEDICAL TECHNOLOGIES's revenue and profit performed over time
Revenue
$9.47M
Gross profit
$5.27M
Operating income
-$7.9M
Net income
-$7.45M
Gross margin
55.6%
Net margin
-78.6%
The company's net margin fell by 42% YoY and by 4.1% QoQ
NMTC's operating margin is down by 42% YoY and by 4.1% from the previous quarter
NEUROONE MEDICAL TECHNOLOGIES's net income has decreased by 40% YoY and by 7% from the previous quarter
The company's operating income fell by 39% YoY and by 7% QoQ

Price vs fundamentals

How does NMTC's price correlate with its fundamentals

Growth

What is NEUROONE MEDICAL TECHNOLOGIES's growth rate over time

Valuation

What is NEUROONE MEDICAL TECHNOLOGIES stock price valuation
P/E
N/A
P/B
3.1
P/S
1.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.08
The EPS has declined by 4.5% since the previous quarter
The P/B is 59% below the 5-year quarterly average of 7.7 and 53% below the last 4 quarters average of 6.8
NEUROONE MEDICAL TECHNOLOGIES's equity has plunged by 54% YoY and by 26% from the previous quarter
The price to sales (P/S) is 96% lower than the 5-year quarterly average of 30.1 and 65% lower than the last 4 quarters average of 3.6
NMTC's revenue is up by 3% since the previous quarter

Efficiency

How efficient is NEUROONE MEDICAL TECHNOLOGIES business performance
The ROS has declined by 42% year-on-year and by 4.1% since the previous quarter
The return on equity has declined by 28% since the previous quarter but it is up by 18% year-on-year
NMTC's ROA is down by 22% from the previous quarter and by 14% YoY
The company's return on invested capital fell by 10% YoY

Dividends

What is NMTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NMTC.

Financial health

How did NEUROONE MEDICAL TECHNOLOGIES financials performed over time
The total assets is 156% greater than the total liabilities
The quick ratio has shrunk by 73% YoY and by 45% QoQ
NMTC's current ratio has dropped by 60% year-on-year and by 33% since the previous quarter
The company's debt is 98% lower than its equity
The company's debt has shrunk by 58% YoY and by 21% QoQ
NEUROONE MEDICAL TECHNOLOGIES's equity has plunged by 54% YoY and by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.